Galmed Pharmaceuticals
GLMD
34 hedge funds and large institutions have $60.6M invested in Galmed Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 13 closing their positions.
16% more capital invested
Capital invested by funds: $52.2M → $60.6M (+$8.36M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.01% less ownership
Funds ownership: 0.2% → 0.2% (-0.01%)
19% less funds holding
Funds holding: 42 → 34 (-8)
22% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 9
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $111K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
+$1.29M |
| 2 |
JP Morgan Chase
New York
|
+$281K |
| 3 |
DG
Delek Group
Herzliya,
Israel
|
+$172K |
| 4 |
Goldman Sachs
New York
|
+$137K |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$726K |
| 2 |
SIM
Spark Investment Management
New York
|
-$507K |
| 3 |
PAM
Premier Asset Management
Chicago,
Illinois
|
-$505K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$321K |
| 5 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
-$297K |
GLMD Hedge Fund Activity: Q1 2019 in Review
34 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2019, worth a combined $60.6M — up 16% from $52.2M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of GLMD and 5 opened new positions — a net loss of 8 holders — while 9 trimmed existing stakes and 7 added.
The largest buyer was Ibex Investors, adding an estimated $1.29M. The largest seller was UBS O'Connor, exiting entirely with an estimated $726K sold.
- 34 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2019, down from 42 in Q4 2018.
- Funds reported $60.6M of Galmed Pharmaceuticals stock for Q1 2019, up 16% quarter-over-quarter.
- 5 funds opened new Galmed Pharmaceuticals positions in Q1 2019 and 13 closed out, a net change of -8 holders.
- The largest Galmed Pharmaceuticals buyer in Q1 2019 was Ibex Investors, an estimated $1.29M added.
- The largest Galmed Pharmaceuticals seller in Q1 2019 was UBS O'Connor, an estimated $726K sold.
Based on aggregated 13F filings for Q1 2019.